News & Updates

An editorial piece published in Hong Kong Medical Journal makes a case for universal access to noninvasive prenatal screening (NIPS) as the first-line screening option within Hong Kong’s public healthcare system – on the basis of women’s preferences and its clinical superiority vs first-trimester combined screening (FTS). [Hong Kong Med J 2026;32:287-290]

Treatment with interleukin (IL)-17 inhibitors in patients with hidradenitis suppurativa does not appear to contribute to an increase in the risk of inflammatory bowel disease (IBD), according to a meta-analysis.

A high positivity rate of antiparietal cell antibody (APCA) is seen among symptomatic patients from South and Southeast Asia, but only a few have severe predominant corpus atrophy or positive pepsinogen tests, reports a study. This finding suggests a low rate of autoimmune gastritis (AIG) in this population.

Letermovir prophylaxis falls short of reducing medication regimen complexity index (MRCI) over time in patients who underwent allogeneic haematopoietic stem cell transplantation (allo-HCT), according to a study.

Patients with ovarian cancer are no strangers to several drug therapy problems (DTPs), particularly adverse drug reactions, suggests a study.

The survival benefit associated with the use of statins in adults treated for colorectal cancer (CRC) is only modest at best, according to a target trial emulation.

Antimicrobial resistance (AMR) in ventilator-associated pneumonia and bloodstream infections in Asia is common and associated with high mortality rates and reduced quality of life, as shown in the ACORN-HAI study.

A smartphone application (app) that helps stabilize circadian rhythm reduces the rate of recurrence and improves the clinical course in patients with major depressive disorder (MDD) or bipolar disorder (BD), according to a study.

The occurrence of an exacerbation, regardless of severity, is associated with accelerated lung function decline in patients with chronic obstructive pulmonary disorder (COPD), according to the Early COPD study.

In patients with type 2 diabetes and moderate risk of cardiovascular disease, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) provide comparable kidney protection, but semaglutide outperforms other agents in terms of preventing or delaying chronic kidney disease and lowering the risk of death, according to a target trial emulation using real-world claims data.